Delving into the Latest Updates on JX2201 with Synapse

Overview

Basic Info

Drug Type

Chemical drugs

Synonyms

Target-

Action-

Mechanism-

Therapeutic Areas

Endocrinology and Metabolic Disease

Active Indication

Lipoprotein Types--Lp System Lp(A) Hyperlipoproteinemia

Inactive Indication-

Originator Organization

Zhejiang Jingxin Pharmaceutical Co., Ltd.

Active Organization

Zhejiang Jingxin Pharmaceutical Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

主要目的：评价参与者单次和多次口服JX2201的安全性和耐受性。次要目的：评价参与者单次和多次口服JX2201的药代动力学特征；评价参与者单次和多次口服JX2201后药效动力学特征；评价高脂饮食对健康参与者口服JX2201后药代动力学特征的影响；初步探索JX2201在健康参与者体内的代谢方式及排泄途径；评价参与者口服JX2201对QT/QTc间期的影响。

[Translation]

Primary purpose: To evaluate the safety and tolerability of single and multiple oral administration of JX2201 in participants. Secondary purpose: To evaluate the pharmacokinetic characteristics of single and multiple oral administration of JX2201 in participants; To evaluate the pharmacodynamic characteristics of single and multiple oral administration of JX2201 in participants; To evaluate the effect of high-fat diet on the pharmacokinetic characteristics of oral administration of JX2201 in healthy participants; To preliminarily explore the metabolism and excretion pathway of JX2201 in healthy participants; To evaluate the effect of oral administration of JX2201 on the QT/QTc interval in participants.

Start Date-

Sponsor / Collaborator

Zhejiang Jingxin Pharmaceutical Co., Ltd.

100 Clinical Results associated with JX2201

Login to view more data

100 Translational Medicine associated with JX2201

Login to view more data

100 Patents (Medical) associated with JX2201

Login to view more data

100 Deals associated with JX2201

Login to view more data